Kawin

Kawin, founded in 2008, is a prominent biotechnology entity listed on the Shanghai Stock Exchange STAR Market under the ticker SSE: 688687. Headquartered in the Beijing Economy-Technology Development Area (BDA), the company operates as a specialized firm within the high-growth life sciences sector. Kawin has established a robust reputation for innovation, consistently recognized as a Zhongguancun Top 100 High-growth Enterprise and a key participant in the Beijing G20 projects.

The company maintains a focused operational footprint with one primary facility located in Beijing, China. Kawin currently supports a workforce of 500-1,000 employees dedicated to advanced research and development initiatives. This operational scale allows the firm to maintain high standards in its technical processes while fostering a collaborative environment for its scientific staff. The company's commitment to R&D remains the cornerstone of its business model, driving its competitive positioning within the domestic biotechnology market.

Throughout its corporate evolution, Kawin has secured strategic partnerships with major investment entities, including Legend Capital, Haitong Capital, Cybernaut, and Lilly Asia Ventures. These collaborations have provided the necessary capital and strategic guidance to scale its operations effectively. Meet Kawin's team to learn more about the leadership and scientific experts driving these initiatives. With a revenue of $191.0M, the company continues to leverage its strong market presence to advance its R&D pipeline and maintain its status as a leader in the Chinese biotechnology landscape.